trending Market Intelligence /marketintelligence/en/news-insights/trending/5Yw3rGmovh-3UIJsF2gvCA2 content esgSubNav
In This List

US FDA approves Dimension Therapeutics' application for urea cycle disorder drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA approves Dimension Therapeutics' application for urea cycle disorder drug

The U.S. FDA accepted Dimension Therapeutics Inc.'s investigational new drug application for DTX301 to treat ornithine transcarbamylase deficiency, a genetic disorder that causes ammonia to accumulate in the blood.

Dimension expects to start a phase 1/2 clinical trial to evaluate the urea cycle disorder drug in patients with the deficiency by the end of 2016.